Neutral Media Coverage Likely to Impact Johnson & Johnson (JNJ) Share Price
News headlines about Johnson & Johnson (NYSE:JNJ) have been trending neutral on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 6,000 news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Johnson & Johnson earned a news impact score of 0.50 on their scale. InfoTrie also gave media stories about the company an news buzz score of 7 out of 10, meaning that recent news coverage is likely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Johnson & Johnson’s ranking:
- Johnson & Johnson to Buy Surgical Robotics Maker Auris (wsj.com)
- Johnson & Johnson buys surgical robotics firm Auris for US$3.4 billion (freemalaysiatoday.com)
- Johnson & Johnson Makes $3.4 Billion Buy Into Robotic Surgery Field (investors.com)
- Johnson & Johnson to Buy Robotic Surgery Company Auris Health for $3.4 Billion (thestreet.com)
- Johnson & Johnson to acquire Auris Health for $3.4B (seekingalpha.com)
JNJ stock opened at $134.45 on Thursday. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The stock has a market capitalization of $355.22 billion, a PE ratio of 16.44, a price-to-earnings-growth ratio of 2.11 and a beta of 0.68.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 12th. Stockholders of record on Tuesday, February 26th will be given a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.68%. The ex-dividend date is Monday, February 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 44.01%.
Johnson & Johnson declared that its board has authorized a stock buyback program on Monday, December 17th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to purchase up to 1.5% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.
JNJ has been the subject of several analyst reports. Raymond James raised their target price on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Credit Suisse Group raised their target price on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Citigroup lowered their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research report on Wednesday, January 2nd. Finally, ValuEngine raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $142.20.
In other news, VP Peter Fasolo sold 166,695 shares of the firm’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $146.41, for a total value of $24,405,814.95. Following the completion of the sale, the vice president now directly owns 155,540 shares in the company, valued at approximately $22,772,611.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Charles Prince bought 2,000 shares of Johnson & Johnson stock in a transaction dated Friday, December 14th. The stock was purchased at an average price of $134.37 per share, with a total value of $268,740.00. Following the completion of the purchase, the director now owns 28,520 shares in the company, valued at $3,832,232.40. The disclosure for this purchase can be found here. Over the last three months, insiders sold 465,746 shares of company stock valued at $67,951,916. Corporate insiders own 0.22% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Neutral Media Coverage Likely to Impact Johnson & Johnson (JNJ) Share Price” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/neutral-media-coverage-likely-to-impact-johnson-johnson-jnj-share-price/2819449.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a Derivative?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.